AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3281603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 31501801 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based CASA system
Number of subjects: 28
Study 27454218 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat applied immediately after exercise
Number of subjects: 60
Study 27454218 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat applied 24 hours after exercise
Number of subjects: 60
Study 27454218 — intervention group
Group type: COMPARATOR
Intervention: Control group (no heat applied)
Number of subjects: 60
Study 26112397 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective Parenting Programme (EPP)
Number of subjects: 412
Study 26112397 — intervention group
Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 412
Study 23608654 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin (1.6 mg/d) for 16 weeks
Number of subjects: 91
Study 23608654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 21691817 — intervention group
Group type: EXPERIMENTAL
Intervention: High Dose Vitamin D2 supplementation (HDD) 50,000 IU capsules weekly for 8 weeks then monthly for 4 months (Stratum A)
Number of subjects: 60
Study 21691817 — intervention group
Group type: EXPERIMENTAL
Intervention: High Dose Vitamin D2 supplementation (HDD) for 16 weeks and then monthly for 2 months (Stratum B)
Number of subjects: 60
Study 21691817 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Stratum A)
Number of subjects: 60
Study 21691817 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Stratum B)
Number of subjects: 60
Study 21691817 — intervention group
Group type: EXPERIMENTAL
Intervention: High Dose Vitamin D2 supplementation (HDD)
Number of subjects: 60
Study 18927482 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver nylon dressing (n = 365)
Number of subjects: 1600
Study 18927482 — intervention group
Group type: COMPARATOR
Intervention: Standard gauze dressing (control, n = 1,235)
Number of subjects: 1600
Study 22813231 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation therapy
Number of subjects: 187
Study 22813231 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 187
Study 22813231 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 187
Study 22813231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 16274602 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ethylene glycol‐based vitrification protocol
Number of subjects: 40
Study 16274602 — intervention group
Group type: COMPARATOR
Intervention: Conventional slow‐freezing protocol
Number of subjects: 40
Study 12860833 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone (500 ng/min)
Number of subjects: 48
Study 12860833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 12860833 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone with L‐NMMA
Number of subjects: 48
Study 12860833 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone with sodium nitroprusside
Number of subjects: 48
Study 12860833 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone with phenylephrine
Number of subjects: 48
Study 9869019 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS (30 mg)
Number of subjects: 356
Study 9869019 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (5 mg)
Number of subjects: 356
Study 7620108 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms SCI‐B‐VAC
Number of subjects: 295
Study 7620108 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms Engerix‐B
Number of subjects: 295
Study 7620108 — intervention group
Group type: COMPARATOR
Intervention: 10 micrograms B‐Hepavac‐II
Number of subjects: 295
Study 2570582 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridazolol alone
Number of subjects: 12
Study 2570582 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine
Number of subjects: 12
Study 2570582 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Ridazolol and Molsidomine
Number of subjects: 12
Study 1249694 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocking waterbeds and auditory stimuli
Number of subjects: 0
Study 1249694 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29708058 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck posture monitoring using an inclinometer during 2 hours of work time
Number of subjects: 40
Study 31748290 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary, customised lifestyle intervention stimulating physical activity, healthy diet, and smoking cessation (if applicable).
Number of subjects: 112
Study 29325336 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.08%
Number of subjects: 80
Study 29325336 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.10%
Number of subjects: 80
Study 29325336 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.12%
Number of subjects: 80
Study 29325336 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.14%
Number of subjects: 80
Study 29325336 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (all doses)
Number of subjects: 80
Study 29325336 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 80
Study 25307476 — intervention group
Group type: EXPERIMENTAL
Intervention: skintrek cream PUVA
Number of subjects: 28
Study 25307476 — intervention group
Group type: EXPERIMENTAL
Intervention: skintrek bath PUVA
Number of subjects: 28
Study 25307476 — intervention group
Group type: EXPERIMENTAL
Intervention: skintrek UVB
Number of subjects: 28
Study 25307476 — intervention group
Group type: COMPARATOR
Intervention: conventional bath PUVA
Number of subjects: 28
Study 25307476 — intervention group
Group type: COMPARATOR
Intervention: NB-UVB
Number of subjects: 28
Study 23349741 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine
Number of subjects: 220
Study 23349741 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 220
Study 23349741 — intervention group
Group type: COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DHAPQ)
Number of subjects: 220
Study 21862301 — intervention group
Group type: EXPERIMENTAL
Intervention: re-esterified omega-3 fatty acid triacylglycerols (n3-FA-rTAGs)
Number of subjects: 150
Study 21862301 — intervention group
Group type: EXPERIMENTAL
Intervention: ethyl-esters (n3-FA-EEs)
Number of subjects: 150
Study 21862301 — intervention group
Group type: COMPARATOR
Intervention: corn oil (placebo)
Number of subjects: 150
Study 18640342 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable barrier film
Number of subjects: 103
Study 18640342 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 103
Study 16816861 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-INF alpha-2a (180 microg or 135 microg/week) and RBV 900 mg/d
Number of subjects: 89
Study 16816861 — intervention group
Group type: COMPARATOR
Intervention: IFNalpha-2a (5 MIU/qod) and RBV 900 mg/d
Number of subjects: 89
Study 16816861 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-INF alpha-2a
Number of subjects: 89
Study 16816861 — intervention group
Group type: COMPARATOR
Intervention: IFNalpha-2a
Number of subjects: 89
Study 12614707 — intervention group
Group type: EXPERIMENTAL
Intervention: Group format of the 'Women take PRIDE' heart disease management program
Number of subjects: 0
Study 12614707 — intervention group
Group type: COMPARATOR
Intervention: Self‐Directed format of the 'Women take PRIDE' heart disease management program
Number of subjects: 0
Study 11145354 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-bottle bonding agents
Number of subjects: 1058
Study 11145354 — intervention group
Group type: COMPARATOR
Intervention: Scotchbond Multi-Purpose
Number of subjects: 1058
Study 11145354 — intervention group
Group type: COMPARATOR
Intervention: Tenure primer
Number of subjects: 1058
Study 11145354 — intervention group
Group type: EXPERIMENTAL
Intervention: Early eruption stage
Number of subjects: 1058
Study 11145354 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior
Number of subjects: 1058
Study 11145354 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary problems
Number of subjects: 1058
Study 11145354 — intervention group
Group type: EXPERIMENTAL
Intervention: Visually apparent variations in enamel
Number of subjects: 1058
Study 8885118 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/kg gentamicin loading dose
Number of subjects: 40
Study 8885118 — intervention group
Group type: COMPARATOR
Intervention: 2.5 mg/kg gentamicin standard dose
Number of subjects: 40
Study 8885118 — intervention group
Group type: EXPERIMENTAL
Intervention: Two SGC after the first dose
Number of subjects: 40
Study 1296606 — intervention group
Group type: EXPERIMENTAL
Intervention: rifampin/trimethoprim
Number of subjects: 243
Study 1296606 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 243
Study 3972525 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 435
Study 3972525 — intervention group
Group type: COMPARATOR
Intervention: diatrizoate
Number of subjects: 435
Study 29967332 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 ug/kg dexmedetomidine + 100 μg sufentanil + 300 μg dexmedetomidine (study group)
Number of subjects: 208
Study 29967332 — intervention group
Group type: COMPARATOR
Intervention: Normal saline + 100 μg sufentanil (control group)
Number of subjects: 208
Study 28621259 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted podiatry intervention including footwear advice, footwear provision, foot orthoses, and foot- and ankle-strengthening exercises
Number of subjects: 1010
Study 28621259 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted podiatry intervention
Number of subjects: 1010
Study 28621259 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1010
Study 24420310 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed warnings on plain packs
Number of subjects: 740
Study 24420310 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial warnings about lung disease and cancer
Number of subjects: 740
Study 24420310 — intervention group
Group type: COMPARATOR
Intervention: Loss-framed warnings on plain packs
Number of subjects: 740
Study 24113055 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Number of subjects: 748
Study 24113055 — intervention group
Group type: COMPARATOR
Intervention: 3-Dimensional Conformal Radiation Therapy (3D-CRT)
Number of subjects: 748
Study 21039720 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment
Number of subjects: 55
Study 21039720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 18283247 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 117
Study 18283247 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 117
Study 18283247 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin
Number of subjects: 117
Study 16553636 — intervention group
Group type: EXPERIMENTAL
Intervention: Florida Probe (FP) (159 N/cm(2))
Number of subjects: 12
Study 16553636 — intervention group
Group type: EXPERIMENTAL
Intervention: Jonker Probe (JP) (153 N/cm(2))
Number of subjects: 12
Study 16553636 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodontic Probe (BP) (255 N/cm(2))
Number of subjects: 12
Study 16553636 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Probe (MP)
Number of subjects: 12
Study 12710219 — intervention group
Group type: EXPERIMENTAL
Intervention: Studying longer, 14-item DRM lists
Number of subjects: 0
Study 12710219 — intervention group
Group type: EXPERIMENTAL
Intervention: Studying shorter DRM lists
Number of subjects: 0
Study 11528574 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone-proguanil
Number of subjects: 976
Study 11528574 — intervention group
Group type: COMPARATOR
Intervention: Mefloquine
Number of subjects: 976
Study 9645716 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-enucleation radiation
Number of subjects: 1003
Study 9645716 — intervention group
Group type: COMPARATOR
Intervention: Enucleation alone
Number of subjects: 1003
Study 7948436 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose surfactant treatment (200 mg/kg)
Number of subjects: 15
Study 7948436 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose surfactant treatment (100 mg/kg)
Number of subjects: 15
Study 3070473 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized salbutamol
Number of subjects: 22
Study 3070473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 31621832 — intervention group
Group type: EXPERIMENTAL
Intervention: CVac-chloroquine arm
Number of subjects: 36
Study 31621832 — intervention group
Group type: EXPERIMENTAL
Intervention: CVac-primaquine/chloroquine arm
Number of subjects: 36
Study 31621832 — intervention group
Group type: COMPARATOR
Intervention: Infectivity controls
Number of subjects: 36
Study 29277607 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastic oleoresin (MO), 15g administered for three days through smoking the episiotomy wound
Number of subjects: 147
Study 29277607 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastic oleoresin (MO)
Number of subjects: 147
Study 29277607 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MO treatment)
Number of subjects: 147
Study 28914126 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigation services
Number of subjects: 0
Study 26261111 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural frequency representation
Number of subjects: 200
Study 26261111 — intervention group
Group type: COMPARATOR
Intervention: Single-event probability format
Number of subjects: 200
Study 23157691 — intervention group
Group type: EXPERIMENTAL
Intervention: Outcome Questionnaire 45 (OQ-45) with feedback
Number of subjects: 374
Study 23157691 — intervention group
Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 374
Study 21738098 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 158
Study 21738098 — intervention group
Group type: COMPARATOR
Intervention: Pain clinic (PC) evaluation with or without treatment
Number of subjects: 158
Study 21738098 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 158
Study 21738098 — intervention group
Group type: COMPARATOR
Intervention: Pain clinic (PC)
Number of subjects: 158
Study 18458035 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 55
Study 18458035 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide/oxygen
Number of subjects: 55
Study 18458035 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide/oxygen plus EMLA
Number of subjects: 55
Study 18458035 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo cream) with nitrous oxide/oxygen
Number of subjects: 55
Study 16449745 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Touch (TT)
Number of subjects: 0
Study 16449745 — intervention group
Group type: EXPERIMENTAL
Intervention: Mimic Therapeutic Touch (MT)
Number of subjects: 0
Study 16449745 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 12958547 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm intermittent blood cardioplegia
Number of subjects: 40
Study 12958547 — intervention group
Group type: COMPARATOR
Intervention: Cold intermittent blood cardioplegia
Number of subjects: 40
Study 10484801 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.2 mg/kg)
Number of subjects: 70
Study 10484801 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (control)
Number of subjects: 70
Study 8564129 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg rhDNase aerosol, twice a day for six consecutive days
Number of subjects: 20
Study 8564129 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhalation
Number of subjects: 20
Study 2021379 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component behavioral treatment package (IBD education, progressive muscle relaxation, thermal biofeedback, cognitive coping strategies)
Number of subjects: 21
Study 2021379 — intervention group
Group type: COMPARATOR
Intervention: Symptom-monitoring (control condition)
Number of subjects: 21
Study 2021379 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component behavioral treatment package
Number of subjects: 21
Study 6217892 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionic contrast media of high osmolality
Number of subjects: 40
Study 6217892 — intervention group
Group type: COMPARATOR
Intervention: Nonionic contrast media or ionic contrast media of low osmolality
Number of subjects: 40
Study 6217892 — intervention group
Group type: EXPERIMENTAL
Intervention: All contrast media used
Number of subjects: 40
Study 29679478 — intervention group
Group type: EXPERIMENTAL
Intervention: bleselumab (0.1, 0.3, 1.0 or 3.0 mg/kg)
Number of subjects: 60
Study 29679478 — intervention group
Group type: EXPERIMENTAL
Intervention: bleselumab (1.0 or 3.0 mg/kg)
Number of subjects: 60
Study 29679478 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 28662313 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CRT) with concurrent cisplatin followed by adjuvant cisplatin plus fluorouracil
Number of subjects: 348
Study 28662313 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 348
Study 26197975 — intervention group
Group type: EXPERIMENTAL
Intervention: Monosodium glutamate (MSG) ingestion (150 mg/kg)
Number of subjects: 16
Study 26197975 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamate (Glu) injection (0.5 M, 0.2 ml)
Number of subjects: 16
Study 26197975 — intervention group
Group type: COMPARATOR
Intervention: NaCl (placebo) injection (0.9%, 0.2 ml)
Number of subjects: 16
Study 26197975 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-injection MSG ingestion
Number of subjects: 16
Study 26197975 — intervention group
Group type: EXPERIMENTAL
Intervention: Glu injections into the masseter muscle
Number of subjects: 16
Study 26197975 — intervention group
Group type: EXPERIMENTAL
Intervention: MSG ingestion and Glu injection in the jaw muscles
Number of subjects: 16
Study 23411522 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational path RPDs
Number of subjects: 40
Study 23411522 — intervention group
Group type: COMPARATOR
Intervention: Linear path RPDs
Number of subjects: 40
Study 21921953 — intervention group
Group type: EXPERIMENTAL
Intervention: Ologen (OLO) implant
Number of subjects: 40
Study 21921953 — intervention group
Group type: COMPARATOR
Intervention: Low-dosage mitomycin-C (MMC)
Number of subjects: 40
Study 18374987 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-item Hamilton Depression Rating Scale (HDRS)
Number of subjects: 42
Study 16584518 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human GH (1-1.5 units/day, 5 days/week)
Number of subjects: 24
Study 16584518 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 24
Study 14623686 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐0 coated polypropylene (Prolene; Ethicon Inc)
Number of subjects: 41
Study 14623686 — intervention group
Group type: COMPARATOR
Intervention: 5‐0 coated irradiated polyglactin 910 (Vicryl Rapide; Ethicon Inc)
Number of subjects: 41
Study 10995263 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorophyllin (CHL)
Number of subjects: 0
Study 10995263 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 8644530 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% carteolol
Number of subjects: 12
Study 8644530 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% dipivefrine
Number of subjects: 12
Study 8644530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1988521 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms/kg ivermectin
Number of subjects: 200
Study 1988521 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 micrograms/kg ivermectin
Number of subjects: 200
Study 1988521 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms/kg ivermectin
Number of subjects: 200
Study 1988521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 1988521 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-monthly dosing
Number of subjects: 200
Study 1988521 — intervention group
Group type: COMPARATOR
Intervention: Yearly dosing (12 and 24 months after initial therapy)
Number of subjects: 200
Study 6346588 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal jet injector
Number of subjects: 388
Study 6346588 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional injection (half a million units)
Number of subjects: 388
Study 6346588 — intervention group
Group type: EXPERIMENTAL
Intervention: Two million units
Number of subjects: 388
Study 6346588 — intervention group
Group type: EXPERIMENTAL
Intervention: One million units
Number of subjects: 388
Study 6346588 — intervention group
Group type: EXPERIMENTAL
Intervention: Four million units (1979 trial)
Number of subjects: 388
Study 6346588 — intervention group
Group type: EXPERIMENTAL
Intervention: Two million units (1979 trial)
Number of subjects: 388
Study 3566845 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisuride (Dopergin) - average dosage 1 mg/d
Number of subjects: 27
Study 3566845 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine - average dosage 10 mg/d
Number of subjects: 27
Study 3566845 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisuride
Number of subjects: 27
Study 3566845 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 27
Study 31594469 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive, computerized working memory training (32 hours)
Number of subjects: 63
Study 31594469 — intervention group
Group type: COMPARATOR
Intervention: Placebo computerized program (32 hours)
Number of subjects: 63
Study 28649914 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Navigation (PN)
Number of subjects: 862
Study 28649914 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 862
Study 27577069 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus sunitinib (n=24)
Number of subjects: 49
Study 27577069 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (n=25)
Number of subjects: 49